Why Is Esperion Therapeutics Stock Trading Higher Today?
Portfolio Pulse from Vandana Singh
Esperion Therapeutics Inc (NASDAQ:ESPR) announced positive results from two CLEAR Outcomes Study Late-Breakers at the European Society of Cardiology Congress 2023. The studies showed that bempedoic acid, a drug used to lower LDL-C, reduced the risk of major adverse cardiovascular events by up to 31%. The drug also demonstrated benefits in patients with diabetes and did not increase rates of new-onset diabetes. Following the announcement, ESPR shares rose by 15.90%.
August 28, 2023 | 6:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Esperion Therapeutics' stock is trading higher following the announcement of positive results from two CLEAR Outcomes Study Late-Breakers. The studies showed that bempedoic acid reduced the risk of major adverse cardiovascular events and did not increase rates of new-onset diabetes.
The positive results from the CLEAR Outcomes Study Late-Breakers indicate that bempedoic acid is effective in reducing the risk of major adverse cardiovascular events. This is likely to increase the demand for the drug, leading to higher revenues for Esperion Therapeutics. The news has already had a positive impact on the company's stock, with shares trading higher.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100